Emcitate Patent Expiration

Emcitate is a drug owned by Rare Thyroid Therapeutics International Ab. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Emcitate's patents will be open to challenges from 28 September, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 07, 2045. Details of Emcitate's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12611383 NA
Jul, 2045

(18 years from now)

Active


FDA has granted several exclusivities to Emcitate. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Emcitate, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Emcitate.

Exclusivity Information

Emcitate holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Emcitate's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 28, 2031

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Emcitate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emcitate's family patents as well as insights into ongoing legal events on those patents.

Emcitate's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Emcitate's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 07, 2045 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Emcitate Generics:

There are no approved generic versions for Emcitate as of now.





About Emcitate

Emcitate is a drug owned by Rare Thyroid Therapeutics International Ab. Emcitate uses Tiratricol as an active ingredient. Emcitate was launched by Rare Thyroid in 2026.

Approval Date:

Emcitate was approved by FDA for market use on 28 September, 2026.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Emcitate is 28 September, 2026, its NCE-1 date is estimated to be 28 September, 2030.

Active Ingredient:

Emcitate uses Tiratricol as the active ingredient. Check out other Drugs and Companies using Tiratricol ingredient

Dosage:

Emcitate is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
350MCG TABLET, FOR SUSPENSION Prescription ORAL